Role of Balanitoside on Hyperglycemia and Oxidative Stress in Diabetic Rats

Wusa Makena1, Wilson Oliver Hamman1, Adebayo Adekunle Buraimoh2 and Nathan Isaac Dibal3*

1Department of Human Anatomy, Ahmadu Bello University Zaria, Nigeria
2Department of Human Anatomy, Kaduna State University, Nigeria
3Department of Human Anatomy, University of Maiduguri, Nigeria

*Corresponding author: Nathan Isaac Dibal, Department of Human Anatomy, University of Maiduguri, PMB 1069 Maiduguri, Borno State, Nigeria, Tel: +2348069088308; Email: nathandibal@gmail.com

Submission: August 08, 2018; Published: October 15, 2018

Abstract

The aim of the study was to evaluate the effect of Balanitoside on hyperglycemia, pancreatic β-cells and oxidative stress in diabetic rats. Eighty diabetic rats were divided into four groups of twenty rats each; group I serve as diabetic control and receive distilled water at 0.5mg/kg, groups II-IV serve as the experimental groups and receive 10mg/kg, 20mg/kg of Balanitoside and 6units/kg of Insulin respectively. Group V serve as the normal control and consist of twenty non-diabetic rats, they were given distilled water at 0.5mg/kg. Five rats from each group were sacrificed on day 8, 15, 22 and 29, the fasting blood glucose levels were monitored on weekly basis. The liver and pancreas were dissected; the liver was homogenized in Phosphate buffer Saline, centrifuged at 5000 x g and used to determine the activities of CAT, SOD and GSH. The pancreas was processed for light microscopic study and stained with H&E and Gomori Aldehyde. The result showed significant reduction in the fasting blood glucose levels of rats treated with Balanitoside and insulin as compared to those of diabetic control (P<0.05), a significant increase in CAT, SOD &GSH levels were observed in rats treated with Balanitoside and insulin as compared with those of diabetic control rats (P<0.05). Regeneration of pancreatic β-cells was observed in rats treated with Balanitoside and insulin. In conclusion, Balanitoside decrease blood glucose levels and oxidative stress in diabetic rats and cause the regeneration of pancreatic β-cells.

Keywords: Balanitoside; Diabetes; Hyperglycemia; Oxidative stress; β-cells

Introduction

Diabetes mellitus (DM) is a chronic disorder characterized by high blood glucose level either as a result of reduction or lack of insulin production or the body’s ineffective use of insulin [1]. DM can be classified into two main categories; type 1 that occurs because of immune destruction of pancreatic β-cells leading to decrease/lack of insulin production and type 2 that occur as a result of tissue insulin resistance characterized by high blood glucose level with normal insulin production [2]. As the need for insulin increases, the pancreas loses its ability to produce insulin leading to relative insulin deficiency [3]. Type 2 diabetes in known to have a strong genetic influence with contributing environmental factor; other contributing factors includes age, sedentary lifestyle, distribution of fat and obesity [4]. Globally, DM is a major health problem and one of the most prevalent endocrine disorder. According to international diabetes federation (IDF), about 382 million people were suffering from diabetes in 2013 and there is an expected increase to 592 million in 2035 [5,6]. Complications of DM includes; cardiomyopathy, dyslipidemia, neuropathy, nephropathy and retinopathy [7,8]. DM can be managed or controlled by either adjusting diet with regular exercise, insulin replacement therapy or the use of oral hypoglycemic drugs [7]. Oxidative stress occurs as a result of reduction in antioxidant capacity which can increase the deleterious effects of free radicals and consequently lead to the development of diabetes complications [9]. Antioxidants scavenge free radicals and peroxides formed during oxidative stress that occur due to disease [10]. Due to the high cost of insulin and most oral hypoglycemic drugs and the side effects associated with their use, there are still challenges in the management of diabetes without side effects [8,11]. Therefore, there is a need for a novel diabetic drug with less or no side effects [12]. The role of many plant extract in the management of diabetes suggest that plants phytochemicals may play important role in drug development. Previous studies revealed that the hypoglycemic effects of most medicinal plants are attributed to their saponin content [13-15]. Balanitosides are saponin from Balanite aegyptiaca fruit, they belong to a large family of structurally related compounds of steroid or triterpenoid aglycone (sapogenin) linked to one or more oligo saccharide moieties by glycosidic linkage, the carbohydrate moiety consists of pentoses, hexoses, or uronic acids. The presence of both polar (sugar) and no polar (steroid or triterpenoid) groups provide saponins with strong surface-active properties which distinguish these compounds from other glycosides [16]. The aim of the study was to evaluate the effect of Balanitoside on hyperglycemia, pancreatic β-cells and oxidative stress markers in diabetic rats.
Materials and Methods

Plant material

The fruit of *Balanite aegyptiaca* were purchased from a local market in Guyuk Local Government of Adamawa State, Nigeria. Identification and authentication of the fruit was done at Herbarium Unit, Department of Biological Sciences, Ahmadu Bello University (ABU) Zaria, Nigeria. Voucher number 2064.

Wistar rats of both sexes weighing between 150-200g were obtained from the Animal House, Department of Pharmacology and Therapeutics, ABU, Zaria. They were fed with grower mash feed (Vital Feeds, Grand cereal, Jos, Nigeria) and provided with water ad libitum. They were acclimatized to the animal house conditions two (2) weeks prior to commencement of the experiment. The research was approved by ABU Zaria research and ethical committee, it was in conformity with the ARRIVE guidelines (reporting of in vivo experiment) and was carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Balanitoside extraction

The coat of *Balanite aegyptiaca* fruit was gently removed the mesocarp (fleshy part) was peeled and air dried at room temperature and grounded into powdered. The powdered mesocarp was defatted by petroleum ether 3x1h at 40°C. Balanitoside was isolated from *Balanite aegyptiaca* fruits using a procedure described by Wiart et al. [17], powdered fruits from *Balanite aegyptiaca* was extracted with petroleum ether (3 times with 1.5L) over 3 days with shaking at ambient temperature and the combined extracts filtered. Then the precipitate extracted with methylene chloride (3 times with 1.5L) over 3 days with shaking at ambient temperature and the combined extracts filtered then the precipitate extracted with ethyl acetate (3 times with 1.5L) over 3 days with shaking at ambient temperature and the combined extracts filtered. The precipitate extracted with methylene chloride (3 times with 1.5L) over 3 days with shaking at ambient temperature and the combined extracts filtered the precipitate extracted with butanol (3 times with 1.5L) over 3 days with shaking at ambient temperature and the combined extracts filtered and evaporated to dryness in a rotary evaporator under reduced pressure.

Tests for saponins

Saponins was identified according to the method described by Ayoola et al. [18] where 0.5g of extract was added 5ml of distilled water in a test tube. The solution was shaken vigorously and some drops of olive oil was added. The formation of stable foam was taken as an indication for the presence of saponins.

Induction of hyperglycemia

Hyperglycemia was induced using *streptozotocin* freshly prepared in 0.1M of citrate buffer (pH 4.5) according to the method described by Al Attar et al. [20]. The rats were fasted overnight with free access to water prior to the induction of hyperglycemia which was carried out by a single intra-peritoneal injection of the *streptozotocin* at 50mg/kg body weight. After 72 hours of *streptozotocin* administration, blood was collected from the tail vein of the rats and the blood glucose concentration were measured with digital glucometer and strips (Accu-Chek® Advantage, Roche Diagnostic, Germany). Rats having fasting blood glucose concentration above 250mg/dL were considered hyperglycemic and selected for the study. The rats were then allowed to stabilize with consistent hyperglycemia for another 15 days before the research.

Experimental design

Eighty (80) diabetic rats were divided into four groups of twenty rats each; group I serve as the diabetic control and receive distilled water through intra-peritoneal injection at 0.5mg/kg, groups II-IV serve as the experimental groups and receive 10mg/kg, 20mg/kg body weight of Balatinoside and 6units/kg body weight of Insulin respectively through intra-peritoneal injection. Group V serve as the normal control and consist of twenty (20) non-diabetic rats, they were given distilled water at 0.5mg/kg. Five rats from each group were sacrificed on day 8 (week 1), day 15 (week 2), day 22 (week 3) and day 29 (week 4). The fasting blood glucose levels of each rat was monitored, the liver of all the rats were dissected out, homogenized in Phosphate buffer Saline (pH 7.4) using a Teflon homogenizer. The homogenate was then centrifuged at 5,000 x g, the supernatant was used to determine the activities of oxidative stress markers i.e. Catalase (CAT) Superoxide Dismutase (SOD) and Glutathione reductase (GSH). The pancreas of rats were dissected out on the 29th day, fixed in neutral buffered formalin (NBF), dehydrated in graded series of alcohol, embedded in paraffin wax, cleared in xylene, sectioned at 5μm using a rotary microtome and stained with Hæmatoxylin and eosin (H&E) and Gomori Aldehyde.

Statistical analysis

The data were analyzed with statistical package for social science (SPSS) version 20 (IBM, USA), one-way analysis of variance (ANOVA) and Turkey post hoc test were used to compare the differences between and within groups. All the data were expressed as Mean±standard deviation (SD) and P<0.05 was considered statistically significant.

Results

There was a significant reduction in the fasting blood glucose levels of rats treated with 10mg/kg & 20mg/kg Balanitoside and 6units/kg insulin as compared to those of diabetic control rats in all the weeks at P<0.05. There was no significant difference in the fasting blood glucose levels between the normal control rats and rats treated with Balanitoside and insulin (P>0.05), see Table 1.
Table 1: Fasting blood glucose levels (mg/dL) of diabetic and non-diabetic rats treated with Balanitoside and insulin.

<table>
<thead>
<tr>
<th>Week</th>
<th>Diabetic Control</th>
<th>10mg/kg Balanitoside</th>
<th>20mg/kg Balanitoside</th>
<th>6units/kg Insulin</th>
<th>Normal Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>435.00±76.41&lt;sup&gt;a&lt;/sup&gt;</td>
<td>132.20±10.21&lt;sup&gt;b&lt;/sup&gt;</td>
<td>141.40±56.59&lt;sup&gt;a&lt;/sup&gt;</td>
<td>171.60±45.39&lt;sup&gt;b&lt;/sup&gt;</td>
<td>106.40±12.42&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>2</td>
<td>517.60±52.32&lt;sup&gt;a&lt;/sup&gt;</td>
<td>131.40±11.63&lt;sup&gt;bc&lt;/sup&gt;</td>
<td>158.20±17.02&lt;sup&gt;c&lt;/sup&gt;</td>
<td>145.40±40.00&lt;sup&gt;b&lt;/sup&gt;</td>
<td>110.80±12.56&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>3</td>
<td>532.80±34.49&lt;sup&gt;a&lt;/sup&gt;</td>
<td>106.20±10.52&lt;sup&gt;bc&lt;/sup&gt;</td>
<td>142.20±27.19&lt;sup&gt;a&lt;/sup&gt;</td>
<td>97.60±11.42&lt;sup&gt;cd&lt;/sup&gt;</td>
<td>110.60±10.28&lt;sup&gt;cd&lt;/sup&gt;</td>
</tr>
<tr>
<td>4</td>
<td>547.80±40.00&lt;sup&gt;a&lt;/sup&gt;</td>
<td>112.60±7.50&lt;sup&gt;bc&lt;/sup&gt;</td>
<td>129.20±7.29&lt;sup&gt;a&lt;/sup&gt;</td>
<td>109.80±18.17&lt;sup&gt;c&lt;/sup&gt;</td>
<td>102.40±8.32&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Values expressed as Mean±SD. Values along the same row with different superscripts a, b, c and d are significantly different (P<0.05).

A significant increase in CAT levels was observed in rats treated with Balanitoside at 10mg/kg & 20mg/kg and 6units/kg insulin as compared with those of diabetic control rats (P<0.05) in week 2. There was no significant difference in CAT levels between diabetic control rats and rats treated with 10mg/kg & 20mg/kg Balanitoside and 6units/kg insulin in weeks 1, 2, and 3 (P>0.05), see Table 2.

Table 2: CAT levels (µ/mg) of diabetic and non-diabetic rats treated with and Balanitoside and insulin.

<table>
<thead>
<tr>
<th>Week</th>
<th>Diabetic Control</th>
<th>10mg/kg Balanitoside</th>
<th>20mg/kg Balanitoside</th>
<th>6units/kg Insulin</th>
<th>Normal Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>44.30±9.61&lt;sup&gt;a&lt;/sup&gt;</td>
<td>50.88±10.24&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>51.61±3.97&lt;sup&gt;b&lt;/sup&gt;</td>
<td>48.52±2.89&lt;sup&gt;cd&lt;/sup&gt;</td>
<td>57.53±6.05&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>2</td>
<td>36.71±3.38&lt;sup&gt;a&lt;/sup&gt;</td>
<td>53.20±3.55&lt;sup&gt;ad&lt;/sup&gt;</td>
<td>50.40±4.09&lt;sup&gt;b&lt;/sup&gt;</td>
<td>45.92±3.64&lt;sup&gt;bc&lt;/sup&gt;</td>
<td>57.40±3.39&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>3</td>
<td>34.27±12.09&lt;sup&gt;a&lt;/sup&gt;</td>
<td>44.18±13.17&lt;sup&gt;a&lt;/sup&gt;</td>
<td>40.30±5.51&lt;sup&gt;cd&lt;/sup&gt;</td>
<td>41.82±9.47&lt;sup&gt;cd&lt;/sup&gt;</td>
<td>57.98±0.61&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>4</td>
<td>32.23±5.99&lt;sup&gt;a&lt;/sup&gt;</td>
<td>40.48±2.73&lt;sup&gt;a&lt;/sup&gt;</td>
<td>41.70±10.27&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>36.06±6.54&lt;sup&gt;a&lt;/sup&gt;</td>
<td>57.18±3.45&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

CAT: Catalase Values expressed as Mean±SD. Values along the same row with different superscripts a, b, c and d are significantly different (P<0.05).

There was a significant increase in the SOD levels of rats treated with 10mg/kg & 20mg/kg Balanitoside and 6units/kg insulin as compared with the diabetic control rats in weeks 1, 2 & 4 (P<0.05) with no significant change between diabetic control rats and rats treated with 10mg/kg & 20mg/kg Balanitoside and 6units/kg insulin in week 3 (P>0.05). A significant reduction in SOD levels were observed in rats treated with 10mg/kg & 20mg/kg Balanitoside and 6units/kg insulin as compared with the normal control rats in weeks 3 & 4 (P>0.05). There was no significant difference in SOD levels between normal control rats and rats treated with 10mg/kg & 20mg/kg Balanitoside in weeks 1 & 2 (P>0.05) see Table 3.

Table 3: SOD level (µg/ml) of diabetic and non-diabetic rats treated with and Balanitoside and insulin.

<table>
<thead>
<tr>
<th>Week</th>
<th>Diabetic Control</th>
<th>10mg/kg Balanitoside</th>
<th>20mg/kg Balanitoside</th>
<th>6units/kg Insulin</th>
<th>Normal Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.98±0.33&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.75±0.18&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1.54±0.21&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1.51±0.09&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1.78±0.08&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>2</td>
<td>0.97±0.27&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.80±0.09&lt;sup&gt;bc&lt;/sup&gt;</td>
<td>1.73±0.14&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1.32±0.51&lt;sup&gt;bc&lt;/sup&gt;</td>
<td>1.87±0.07&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>3</td>
<td>0.92±0.23&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.13±0.12&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.05±0.11&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.93±0.33&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1.82±0.12&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>4</td>
<td>0.80±0.12&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.10±0.10&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.04±0.20&lt;sup&gt;bc&lt;/sup&gt;</td>
<td>1.37±0.06&lt;sup&gt;bc&lt;/sup&gt;</td>
<td>1.82±0.12&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

SOD: Superoxide Dismutase Values expressed as Mean±SD. Values along the same row with different superscripts a, b, c and d are significantly different (P<0.05).

A significant increase in GSH level was observed in rats treated with 10mg/kg & 20mg/kg Balanitoside and 6units/kg insulin as compared with the diabetic control rats in week 1 (P<0.05) with no significant change between diabetic control and rats treated with 20mg/kg Balanitoside and 6units/kg insulin in weeks 2, 3 & 4 (P>0.05). There was a significant increase in GSH levels of rats treated with Balanitoside at 10mg/kg as compared with diabetic control rats in weeks 2, 3 & 4 (P<0.05) with no significant change between those of normal control rats and rats treated with Balanitoside at 10mg/kg in all the weeks (P>0.05), see Table 4.
Table 4: GSH levels (µg/ml) of diabetic and non-diabetic rats treated with and Balanitoside and insulin.

<table>
<thead>
<tr>
<th>Week</th>
<th>Diabetic Control</th>
<th>10mg/kg Balanitoside</th>
<th>20mg/kg Balanitoside</th>
<th>6units/kg insulin</th>
<th>Normal Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>14.33±1.19\textsuperscript{a}</td>
<td>27.12±5.59\textsuperscript{bc}</td>
<td>20.68±1.89\textsuperscript{b}</td>
<td>20.50±3.32\textsuperscript{a}</td>
<td>28.18±3.92\textsuperscript{c}</td>
</tr>
<tr>
<td>2</td>
<td>17.27±1.64\textsuperscript{a}</td>
<td>25.59±4.32\textsuperscript{b}</td>
<td>21.26±4.31\textsuperscript{ab}</td>
<td>18.25±1.23\textsuperscript{a}</td>
<td>24.28±1.34\textsuperscript{b}</td>
</tr>
<tr>
<td>3</td>
<td>17.4 ±1.39\textsuperscript{a}</td>
<td>25.85±7.17\textsuperscript{b}</td>
<td>21.54±1.67\textsuperscript{ab}</td>
<td>19.26±2.54\textsuperscript{ab}</td>
<td>25.31±1.88\textsuperscript{b}</td>
</tr>
<tr>
<td>4</td>
<td>16.79±2.83\textsuperscript{a}</td>
<td>21.81±0.77\textsuperscript{bc}</td>
<td>18.67±3.61\textsuperscript{ab}</td>
<td>16.14±3.15\textsuperscript{a}</td>
<td>24.62±2.62\textsuperscript{c}</td>
</tr>
</tbody>
</table>

GSH: Glutathione Reductase Values expressed as Mean±SD. Values along the same row with different superscripts a, b, c and d are significantly different (P<0.05).

Figure 1: Photomicrograph of pancreas of normal control rats A, diabetic control rats B, rats treated with Balanitoside at 10mg/kg C, and 20mg/kg D, and rats treated with 6units/kg insulin E, showing pancreatic islets I with β-cells. H & E stain X250.

Figure 2: Photomicrograph of pancreas of normal control rats A, diabetic control rats B, rats treated with Balanitoside at 10mg/kg C, and 20mg/kg D, and rats treated with 6units/kg insulin E, showing pancreatic islets I with β-cells. Gomori Aldehyde Fulchsin Stain X250.
The photomicrograph of pancreas of normal control rats showed normal architecture of the pancreas with normal β-cell [Figure 1A & 2A, photomicrograph of diabetic control rats showed degeneration of pancreatic β-cells Figure 1B & 2B photomicrograph of rats treated with Balanitoside at 10mg/kg & 20mg/kg showed regeneration of pancreatic β-cells [Figure 1C, 1D, 2C & 2D] while the photomicrograph of pancreas of rats treated with 6 units/kg insulin showed regeneration of the pancreatic β-cells with intercellular figure 1E & 2E.

Discussion

The significant decrease in the fasting blood glucose levels of rats treated with Balanitoside in all the weeks is an indication that Balanitoside at 10mg/kg and 20mg/kg is capable of treating hyperglycemia. However, 6units/kg insulin gave a better effect than Balanitoside, these agrees with earlier study [21] which showed an association between higher incidences of hypoglycemia with intensive diabetes treatment. The possible mechanisms through which Balanitoside brings about its anti-hyperglycemic action in diabetic rats may be by potentiating the insulin effect of plasma from the existing β-cells or by its release from the bound form. The significant increase in the levels of CAT, SOD and GSH in rats treated with Balanitoside at 10mg/kg and 20mg/kg is an indication that Balanitoside can increase the activities of oxidative stress markers by scavenging free radicals to reduce oxidative stress that usually occur because of diabetes mellitus. The non-significant difference in the levels of CAT, SOD and GSH between rats treated with Balanitoside at 10mg/kg and 20mg/kg and 6units/kg insulin shows that Balanitoside is as effective as insulin in scavenging free radicals. CAT, SOD and GSH are crucial cellular components of the body’s antioxidant defense system. Thus, they play an important role in the maintenance of a balanced redox status [10]. SOD maintains the cellular levels of $O_2^{−}$ by converting $O_2•−$ to $H_2O_2$, a more stable reactive oxygen species (ROS) while CAT and GSH metabolizes $H_2O_2$ to $O_2$ and $H_2O$.[22] Earlier studies showed that over expression of antioxidant enzymes in islets or transgenic mice and antioxidants such as N-acetyl-L-cysteine (NAC) protect against ROS-induced β-cell toxicity [23]. As the result in the activities of oxidative stress markers that occur as a result of Balanitoside is more in weeks 1&2 as compare to weeks 3&4; this might be due to increase in unstable ROS with the progressive of diabetes that will require more antioxidant to reduce the oxidative stress [24,25].

The degeneration/degranulation of pancreatic β-cells of diabetic control rats showed that streptozotocin is capable of inducing hyperglycemia by destroying pancreatic β-cells [26,27]. The regeneration of pancreatic β-cells in rats treated with Balanitoside suggest the presence of stable cells in the islets with the ability of regenerating β-cells [28]. This also suggests that Balanitoside at 10mg/kg and 20mg/kg has the ability of inducing the quiescent cells to proliferate and replace the lost cells; The antioxidant properties of Balanitoside may have stopped further destruction of the remaining β-cells by mopping up the circulating ROS generated by the Streptozotocin and then allowing the Balanitoside to induce regenerative activities.

Conclusion

The present study showed that Balanitoside is capable of decreasing blood glucose level of diabetic rats by preventing further destruction of pancreatic β-cells as a result of streptozotocin action and increasing the activities of oxidative stress markers (SOD, GSH and CAT) leading to decrease in oxidative stress.

Author’s contribution

Conception and design: WM, WOH & AAB, Administrative support: WOH & AAB, Provision of study materials: WM & NID, Collection and assembly of data: WM & NID, Data analysis and interpretation: All authors, Manuscript writing: All authors, Final approval of manuscript: All authors.

References


Copyright © Makena et al

How to cite this article: Makena W, Hamman W O, Buraimoh A A, Dibal N I. Role of Balanitoside on Hyperglycemia and Oxidative Stress in Diabetic Rats. 2(2). DOI: 10.31031/IOD.2018.02.000532


